Instituto do Câncer do Estado de São Paulo - HC/ICESP

URI Permanente desta comunidade

O Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira"(ICESP) foi inaugurado em maio de 2008, numa parceria entre o Governo do Estado de São Paulo, a Fundação Faculdade de Medicina (FFM) e a Faculdade de Medicina da Universidade de São Paulo (FMUSP), para ser uma referência em atendimento humanizado, ensino e pesquisa do câncer em âmbito nacional e internacional.

Especializado no tratamento de casos de câncer de alta complexidade, o Instituto foi concebido e equipado para fornecer atenção integral ao paciente oncológico, do tratamento à reabilitação, e dispõe de um Centro de Treinamento em Oncologia onde as equipes de assistência recebem capacitações práticas e teóricas de forma constante.

O ICESP também conta com o apoio de uma equipe multiprofissional (psicólogos, fonoaudiólogos, nutricionistas, assistentes sociais, entre outros) que se dedica aos pacientes e familiares, buscando acolhê-los nesse momento de fragilidade física e emocional.

Site oficial: http://www.icesp.org.br/

Índice h

Scopus: 112

Navegar

Coleções desta Comunidade

Agora exibindo 1 - 3 de 3

Submissões Recentes

article 0 Citação(ões) na Scopus
A Case Study of a Rare Undifferentiated Spindle Cell Sarcoma of the Penis: Establishment and Characterization of Patient-Derived Models
(2024) SOUSA, Ariane Cavalcante dos Santos; FERNANDES, Bruno Leonardo Nascimento Correa; SILVA, Jeronimo Paulo Assis da; STEVANATO FILHO, Paulo Roberto; COIMBRA, Luiza Bitencourt de Carvalho Terci; BESERRA, Adriano de Oliveira; ALVARENGA, Ana Luiza; MAIDA, Giovanna; GUIMARAES, Camila Tokumoto; NAKAMUTA, Ingrid Martinez; MARCHI, Fabio Albuquerque; ALVES, Camila; LICHTENFELS, Martina; FARIAS, Caroline Brunetto de; KUPPER, Bruna Elisa Catin; COSTA, Felipe D'Almeida; MELLO, Celso Abdon Lopes de; CARRARO, Dirce Maria; TORREZAN, Giovana Tardin; LOPES, Ademar; SANTOS, Tiago Goss dos
Rare sarcomas present significant treatment challenges compared to more prevalent soft tissue sarcomas due to limited treatment options and a poor understanding of their biology. This study investigates a unique case of penile sarcoma, providing a comprehensive morphological and molecular analysis. Through the creation of experimental patient-derived models-including patient-derived xenograft (PDX), 3D, and monolayer primary cultures-we successfully replicated crucial molecular traits observed in the patient's tumor, such as smooth muscle actin and CD99 expression, along with specific mutations in genes like TSC2 and FGFR4. These models are helpful in assessing the potential for an in-depth exploration of this tumor's biology. This comprehensive approach holds promise in identifying potential therapeutic avenues for managing this exceedingly rare soft tissue sarcoma.
article 0 Citação(ões) na Scopus
Increased risk of bladder cancer recurrence due to bacillus Calmette-Guérin shortage in Brazil
(2024) MURTA, Claudio Bovolenta; HAYEK, Kayann Kaled Reda El; DIAS, Bruno Cesar; YORIOKA, Marco Aurelio Watanabe; CASSAO, Valter DellAcqua; CLARO, Joaquim Francisco de Almeida
OBJECTIVE: Our study aimed to evaluate the impact of bacillus Calmette-Guerin shortage on recurrence and progression in patients with non-muscle invasive bladder cancer in a Brazilian cohort. METHODS: We retrospectively reviewed the clinicopathological data of 409 patients who had their first transurethral resection of the bladder tumor for intermediate or high-risk non-muscle invasive bladder cancer between June 2014 and May 2021 in a tertiary public hospital in Brazil. Patients included had non-muscle-invasive urothelial carcinoma of the bladder resected completely for the first time, regardless of bacillus Calmette-Guerin use. Low-risk disease patients were excluded from the analysis. Demographic, clinicopathological, and bacillus Calmette-Guerin use data were collected from our database. Recurrence and progression data were obtained from patient records or through telephone interviews. Recurrence-free survival and progression-free survival were calculated from the date of transurethral resection of the bladder tumor until the events of recurrence, progression, last office visit, or phone interview. RESULTS: Within a median follow-up period of 26.7 months, 168 (41.1%) patients experienced a recurrence in a median time of 27 months (95%CI 16.1-38). Bacillus Calmette-Guerin was administered to 57 (13.9%) individuals after transurethral resection of the bladder tumor. Patients with >= 3 lesions (p<0.001), those with lesions >3 cm (p=0.02), and those without bacillus Calmette-Guerin treatment (p<0.001) had shorter recurrence-free survival. According to a Cox multivariate regression model, bacillus Calmette-Guerin use was independently associated with a reduced recurrence rate, with an HR of 0.43 (95%CI 0.25-0.72). Out of the patients studied, 26 (6.4%) experienced progression. T1 stage (p<0.001) and high-grade (p<0.001) were associated with shorter progression-free survival. Bacillus Calmette-Guerin did not influence bladder cancer progression. In the Cox multivariate analysis, high-risk disease was independently associated with progression (p<0.001). CONCLUSION: Our study confirms that non-muscle invasive bladder cancer exhibits a high recurrence rate. The use of adjuvant bacillus Calmette-Guerin in intermediate and high-risk patients significantly reduces this rate. Furthermore, the bacillus Calmette-Guerin shortage could have negatively impacted these patients.
article 0 Citação(ões) na Scopus
TGFβ signaling pathway in salivary gland tumors
(2024) GOMES, Agatha Nagli de Mello; OLIVEIRA, Katia Klug; MARCHI, Fabio Albuquerque; BETTIM, Barbara Beltrame; GERMANO, Janaina Naiara; GONCALVES FILHO, Joao; PINTO, Clovis Antonio Lopes; LOURENCO, Silvia Vanessa; COUTINHO-CAMILLO, Claudia Malheiros
Objective: Pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC), and adenoid cystic carcinoma (ACC) are the most prevalent salivary gland tumors. Their pathogenesis has been recently associated with complex molecular cascades, including the TGF beta signaling pathway. The aim of this study was to evaluate the expression of genes associated with the TGF beta signaling pathway (TGFB1, ITGB6, SMAD2, SMAD4, FBN1, LTBP1, and c-MYC) to map possible downstream alterations in the TGF beta cascade. Design: Thirteen PA, 17 MEC, 13 ACC, and 10 non-neoplastic salivary gland samples were analyzed by real-time RT-PCR. Results: Cases of PA presented increased TGFB1, LTPB1, c-MYC, and FBN1 expressions, whereas SMAD2 expression was decreased when compared to non-neoplastic tissue. MEC patients displayed increased expressions of TGFB1, ITGB6, FBN1, and c-MYC and decreased expressions of SMAD2 and SMAD4. ACC cases exhibited elevated expressions of the investigated genes except TGFB1. The present results suggest that decreased expression of SMAD2 and SMAD4 does not impede the transcriptional regulation of c-MYC, especially in PA and MEC. Increased expressions of ITGB6, TGFB1, LTBP1, and FBN1 appear to be related to the regulation of the TGF beta signaling pathway in these tumors. Additionally, we observed a higher expression of SMAD4 in ACC and a raised expression of ITGB6 and lowered expression of SMAD2 in MEC. Conclusions: Our study demonstrated the differential expression of TGF beta cascade members in salivary gland tumors such as SMAD2/SMAD4 and c-MYC as well as the participation of ITGB6, TGFB1, LTBP1, and FBN1, contributing to the understanding of the mechanisms involved in tumor progression.
article 0 Citação(ões) na Scopus
article 0 Citação(ões) na Scopus
Oral cancer screening outcomes in the Latin American region with special relevance to Brazil and Cuba: a systematic review
(2024) PEDROSO, Caique Mariano; NORMANDO, Ana Gabriela; PEREZ-DE-OLIVEIRA, Maria Eduarda; SIMONATO, Luciana Estevam; GOES, Mario Fernando de; RIBEIRO, Ana Carolina Prado; BRANDAO, Thais Bianca; LOPES, Marcio Ajudarte; WARNAKULASURIYA, Saman; SANTOS-SILVA, Alan Roger
Background: The Latin American region represents a hotspot for oral cancer incidence and mortality. To reduce oral cancer mortality rates, screening for early detection of subjects with suspicious or innocuous oral lesions has been promoted. A systematic review was performed to assess the outcomes of oral cancer screening in the Latin American region. Material and Methods: An electronic search was conducted in eight databases and grey literature. The eligibility criteria included screening where adult participants underwent any screening test during an organized screening program. Screening programs were assessed to understand trends in oral cancer diagnosis. Rates of oral cancers diagnosed in screening programs were classified as increase, decrease, or stable based on each year assessed. Results: Following our searches, twelve studies conducted in Brazil and Cuba were included. The screening tests reported were visual oral examination (VOE) and in one study in addition light -based fluorescence testing. 13,277,608 individuals were screened and a total of 1,516 oral cancers were detected (0.01%). Only two studies aimed to screen high -risk individuals (smokers and drinkers). Oral cancer cases diagnosed during screening programs were proportionately stable over the years 1997 to 2009 but increased from 2010 to 2021. The fluorescenceassociated VOE test demonstrated a sensitivity of 100% and a specificity of 90%. Similarly, the VOE test alone exhibited a sensitivity of 100%, with specificity ranging from 75% to 90%. Conclusions: Screening studies conducted in Latin American countries had serious limitations both in methodology (lack of examiner training) and in reporting data (lack of description of clinical categories of screen positives).Capacitation of health workers to perform VOE in well -designed screening programs should be implemented.
article 0 Citação(ões) na Scopus
Slide tracheoplasty for congenital tracheal stenosis with involvement of the carina and bronchi: a case report
(2024) MINAMOTO, Fabio Eiti Nishibe; CREMONESE, Mariana Rodrigues; WEREBE, Eduardo de Campos; NUDELMAN, Victor; MINAMOTO, Helio
A female newborn presented with respiratory distress at birth and was diagnosed with congenital tracheal stenosis. The stenosis was positioned at the distal trachea and compromised the carina and the right and left bronchi. She underwent surgical treatment using circulatory life support with veno-arterial peripheral extracorporeal membrane oxygenation, and the airway was reconstructed using the slide tracheoplasty technique to build a neocarina. The patient had an excellent postoperative course, was successfully weaned from extracorporeal membrane oxygenation and invasive ventilation, and was discharged.
article 0 Citação(ões) na Scopus
Prognosis value of heat-shock proteins in esophageal and esophagogastric cancer: A systematic review and meta-analysis
(2024) NAKAMURA, Eric Toshiyuki; PARK, Amanda; PEREIRA, Marina Alessandra; KIKAWA, Daniel; TUSTUMI, Francisco
BACKGROUND Heat shock proteins (HSPs) are molecular chaperones that play an important role in cellular protection against stress events and have been reported to be overexpressed in many cancers. The prognostic significance of HSPs and their regulatory factors, such as heat shock factor 1 (HSF1) and CHIP, are poorly understood. AIM To investigate the relationship between HSP expression and prognosis in esophageal and esophagogastric cancer. METHODS A systematic review was conducted in accordance with PRISMA recommendations (PROSPERO: CRD42022370653), on Embase, PubMed, Cochrane, and LILACS. Cohort, case-control, and cross-sectional studies of patients with esophagus or esophagogastric cancer were included. HSP-positive patients were compared with HSP-negative, and the endpoints analyzed were lymph node metastasis, tumor depth, distant metastasis, and overall survival (OS). HSPs were stratified according to the HSP family, and the summary risk difference (RD) was calculated using a random-effect model. RESULTS The final selection comprised 27 studies, including esophageal squamous cell carcinoma (21), esophagogastric adenocarcinoma (5), and mixed neoplasms (1). The pooled sample size was 3465 patients. HSP40 and 60 were associated with a higher 3-year OS [HSP40: RD = 0.22; 95% confidence interval (CI): 0.09-0.35; HSP60: RD = 0.33; 95%CI: 0.17-0.50], while HSF1 was associated with a poor 3-year OS (RD = -0.22; 95%CI: -0.32 to -0.12). The other HSP families were not associated with long-term survival. HSF1 was associated with a higher probability of lymph node metastasis (RD = -0.16; 95%CI: -0.29 to -0.04). HSP40 was associated with a lower probability of lymph node dissemination (RD = 0.18; 95%CI: 0.03-0.33). The expression of other HSP families was not significantly related to tumor depth and lymph node or distant metastasis. CONCLUSION The expression levels of certain families of HSP, such as HSP40 and 60 and HSF1, are associated with long-term survival and lymph node dissemination in patients with esophageal and esophagogastric cancer.
article 0 Citação(ões) na Scopus
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial
(2024) KATO, Ken; DOKI, Yuichiro; CHAU, Ian; XU, Jianming; WYRWICZ, Lucjan; MOTOYAMA, Satoru; OGATA, Takashi; KAWAKAMI, Hisato; HSU, Chih-Hung; ADENIS, Antoine; HAJBI, Farid El; BARTOLOMEO, Maria Di; BRAGHIROLI, Maria Ignez; HOLTVED, Eva; MAKINO, Tomoki; MURPHY, Mariela Blum; AMAYA-CHANAGA, Carlos; PATEL, Apurva; HU, Nan; MATSUMURA, Yasuhiro; KITAGAWA, Yuko; AJANI, Jaffer
Background: First-line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in the CheckMate 648 trial, leading to approvals of both nivolumab-containing regimens in many countries. We report longer-term follow-up data. Methods: This open-label, phase III trial (NCT03143153) enrolled adults with previously untreated, unresectable, advanced, recurrent, or metastatic ESCC. Patients were randomized 1:1:1 to nivolumab plus chemotherapy, nivolumab plus ipilimumab, or chemotherapy. Primary endpoints were OS and progression-free survival (PFS) by blinded independent central review. Hierarchical testing was performed first in patients with tumor cell programmed death ligand 1 (PD-L1) expression of >= 1% and then in the overall population. Results: A total of 970 patients were randomly assigned. After 29 months of minimum follow-up, nivolumab plus chemotherapy continued to demonstrate improvement in OS versus chemotherapy (hazard ratio [HR] = 0.59 [95% CI: 0.46-0.76]) in patients with tumor cell PD-L1 expression of >= 1% and in the overall population (HR = 0.78 [95% CI: 0.65-0.93]) and with nivolumab plus ipilimumab versus chemotherapy (HR = 0.62 [95% CI: 0.48-0.80]) in patients with tumor cell PD-L1 expression of >= 1% and in the overall population (HR = 0.77 [95% CI: 0.65-0.92]). In patients with tumor cell PD-L1 expression of >= 1%, nivolumab plus chemotherapy demonstrated PFS benefit versus chemotherapy (HR = 0.67 [95% CI: 0.51-0.89]); PFS benefit was not observed with nivolumab plus ipilimumab versus chemotherapy (HR = 1.04 [95% CI: 0.79-1.36]). Among all treated patients (n = 936), Grade 3-4 treatment-related adverse events were reported in 151 (49%, nivolumab plus chemotherapy), 105 (32%, nivolumab plus ipilimumab), and 110 (36%, chemotherapy) patients. Conclusions: Nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful OS benefit versus chemotherapy with no new safety signals identified with longer follow-up, further supporting use as first-line standard treatment options for patients with advanced ESCC.
article 0 Citação(ões) na Scopus
article 0 Citação(ões) na Scopus
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-RefractoryDifferentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study
(2024) CAPDEVILA, Jaume; KRAJEWSKA, Jolanta; HERNANDO, Jorge; ROBINSON, Bruce; SHERMAN, Steven I.; JARZAB, Barbara; LIN, Chia-Chi; VAISMAN, Fernanda; HOFF, Ana O.; HITRE, Erika; BOWLES, Daniel W.; WILLIAMSON, Denise; LEVYTSKYY, Roman; OLIVER, Jennifer; KEAM, Bhumsuk; BROSE, Marcia S.
Background: Lenvatinib and sorafenib are standard of care first-line treatments for advanced, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). However, most patients eventually become treatment-resistant and require additional therapies. The phase 3 COSMIC-311 study investigated cabozantinib in patients with RAIR DTC who progressed on lenvatinib, sorafenib, or both and showed that cabozantinib provided substantial clinical benefit. Presented in this study is an analysis of COSMIC-311 based on prior therapy and histology.Methods: Patients were randomized 2:1 (stratification: prior lenvatinib [yes/no]; age [<= 65, >65 years]) to oral cabozantinib (60 mg tablet/day) or matched placebo. Eligible patients received 1-2 prior vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors for DTC (lenvatinib or sorafenib required), had a confirmed DTC diagnosis, and were refractory to or ineligible for radioiodine therapy. For this analysis, progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by a blinded independent radiology committee were evaluated by prior therapy (lenvatinib only, sorafenib only, both) and histology (papillary, follicular, oncocytic, poorly differentiated).Results: Two hundred fifty-eight patients were randomized (170 cabozantinib/88 placebo) who previously received sorafenib only (n = 96), lenvatinib only (n = 102), or both (n = 60). The median follow-up was 10.1 months. The median PFS (months) with cabozantinib/placebo was 16.6/3.2 (sorafenib only: hazard ratio [HR] 0.13 [95% confidence interval, CI, 0.06-0.26]), 5.8/1.9 (lenvatinib only: HR 0.28 [95% CI 0.16-0.48]), and 7.6/1.9 (both: HR 0.27 [95% CI 0.13-0.54]). The ORR with cabozantinib/placebo was 21%/0% (sorafenib only), 4%/0% (lenvatinib only), and 8%/0% (both). Disease histology consisted of 150 papillary and 113 follicular, including 43 oncocytic and 36 poorly differentiated. The median PFS (months) with cabozantinib/placebo was 9.2/1.9 (papillary: HR 0.27 [95% CI 0.17-0.43]), 11.2/2.5 (follicular: HR 0.18 [95% CI 0.10-0.31]), 11.2/2.5 (oncocytic: HR 0.06 [95% CI 0.02-0.21]), and 7.4/1.8 (poorly differentiated: HR 0.18 [95% CI 0.08-0.43]). The ORR with cabozantinib/placebo was 15%/0% (papillary), 8%/0% (follicular), 11%/0% (oncocytic), and 9%/0% (poorly differentiated). Safety outcomes evaluated were consistent with those previously observed for the overall population.Conclusions: Results indicate that cabozantinib benefits patients with RAIR DTC, regardless of prior lenvatinib or sorafenib treatments or histology.